Erythrocytosis in patients taking long-term hemodialysis: A case series
Abstract
Anemia is one of the common findings and complications in patients with end-stage kidney disease (ESRD). Most patients need to take the therapies to control target hemoglobin level and these treatments can add to the high cost and adverse events in these patients. In our hemodialysis center, regular monitoring of hemoglobin was done for all regular hemodialysis patients and we found that two patients who have different etiologies of ESRD had high hemoglobin levels without the help of erythropoietin stimulating agents and blood transfusion. They had the duration of hemodialysis for more than 10 years and they were found to have acquired cystic kidney disease at the time of assessing the etiologies of erythrocytosis. There are few case reports and research about erythrocytosis due to acquired cystic kidney disease. Acquired cystic kidney disease is frequently found in patients with longer duration of dialysis and erythrocytosis is one of the beneficial consequences for chronic kidney disease patients. It can avoid the high cost of erythropoietin-stimulating agent and iron therapy, and their adverse events. Phlebotomy is an easy way to maintain the level of hemoglobin in such patients.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.